Alectinib Hcl
Brand name: Alecensa
Rank #268 of 500 drugs by total cost
$45.7M
Total Cost
2,686
Total Claims
$45.7M
Total Cost
169
Prescribers
$17K
Cost per Claim
0
Beneficiaries
2,749
30-Day Fills
$271K
Avg Cost/Provider
16
Avg Claims/Provider
About Alectinib Hcl
Alectinib Hcl (sold as Alecensa) was prescribed 2,686 times by 169 Medicare Part D providers in 2023, costing the program $45.7M. At $17K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 265 | Losartan/Hydrochlorothiazide (Losartan-Hydrochlorothiazide) | $46.3M | 2,039,676 |
| 266 | Darunavir (Prezista) | $46.0M | 21,793 |
| 267 | C1 Esterase Inhibitor (Haegarda) | $45.8M | 894 |
| 268 | Alectinib Hcl (Alecensa) | $45.7M | 2,686 |
| 269 | Ipratropium Bromide (Ipratropium Bromide) | $45.4M | 656,249 |
| 270 | Amantadine Hcl (Amantadine) | $45.2M | 173,840 |
| 271 | Insulin Nph Human Isophane (Humulin N) | $44.9M | 172,714 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology